Story perspectives

Breakthrough Nasal Drops Show Promise Against Glioblastoma

11/26/2025

Summary

Story summary

Washington University researchers developed nasal drops that travel from the nose to the central nervous system to target glioblastoma.
In preliminary tests on mice, the drops inhibited tumor growth.
The treatment uses nanotechnology to deliver STING-activating molecules that boost the immune response.
When combined with other drugs, the drops induced long-term immunity in mice.
Glioblastoma has a five-year survival rate of 6.9%, highlighting the need for improved treatments.

1 of 1

Story summary

Washington University researchers developed nasal drops that travel from the nose to the central nervous system to target glioblastoma.
In preliminary tests on mice, the drops inhibited tumor growth.
The treatment uses nanotechnology to deliver STING-activating molecules that boost the immune response.
When combined with other drugs, the drops induced long-term immunity in mice.
Glioblastoma has a five-year survival rate of 6.9%, highlighting the need for improved treatments.